Table 2

Results of univariate analysis and multivariate analysis for acute GVHD, chronic GVHD, nonrelapse mortality, relapse, disease-free survival, and overall survival

OutcomeHR (95% CI)P
Univariate analysis   
Grade 2-4 acute GVHD   
    ATG regimen vs T cell–replete regimen 0.98 (0.83-1.16) .82 
    Alemtuzumab regimen vs T cell–replete regimen 0.43 (0.31-0.59) < .0001 
    ATG regimen vs alemtuzumab regimen 2.29 (1.66-3.16) < .0001 
Grade 3-4 acute GVHD   
    ATG regimen vs T cell–replete regimen 0.94 (0.75-1.72) .58 
    Alemtuzumab regimen vs T cell–replete regimen 0.50 (0.33-0.75) .0008 
    ATG regimen vs alemtuzumab regimen 1.89 (1.24-2.89) .003 
Chronic GVHD   
    ATG regimen vs T cell–replete regimen 0.72 (0.62-0.85) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 0.39 (0.29-0.52) < .0001 
    ATG regimen vs alemtuzumab regimen 1.87 (1.38-2.52) < .0001 
Non-relapse mortality   
    ATG regimen vs T cell–replete regimen 1.38 (1.12-1.71) .003 
    Alemtuzumab regimen vs T cell–replete regimen 1.09 (0.79-1.51) .60 
    ATG regimen vs alemtuzumab regimen 1.27 (0.91-1.78) .17 
Relapse   
    ATG regimen vs T cell–replete regimen 1.56 (1.33-1.83) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.60 (1.29-1.99) < .0001 
    ATG regimen vs alemtuzumab regimen 0.97 (0.78-1.21) .80 
Treatment failure (inverse of disease-free survival)   
    ATG regimen vs T cell–replete regimen 1.49 (1.31-1.70) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.41 (1.18-1.70) .0002 
    ATG regimen vs alemtuzumab regimen 1.06 (0.88-1.27) .55 
Overall mortality   
    ATG regimen vs T cell–replete regimen 1.34 (1.17-1.54) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.10 (0.90-1.35) .35 
    ATG regimen vs alemtuzumab regimen 1.22 (0.99-1.50) .07 
Multivariate analysis   
Grade 2-4 acute GVHD*   
    ATG regimen vs T cell–replete regimen 0.88 (0.74-1.04) .12 
    Alemtuzumab regimen vs T cell–replete regimen 0.33 (0.24-0.46) < .001 
    ATG regimen vs alemtuzumab regimen 2.66 (1.91-3.70) < .001 
Grade 3-4 acute GVHD†   
    ATG regimen vs T cell–replete regimen 0.86 (0.69-1.08) .19 
    Alemtuzumab regimen vs T cell–replete regimen 0.42 (0.27-0.64) < .001 
    ATG regimen vs alemtuzumab regimen 2.08 (1.34-3.21) < .001 
Chronic GVHD‡   
    ATG regimen vs T cell–replete regimen 0.69 (0.59-0.81) < .001 
    Alemtuzumab regimen vs T cell–replete regimen 0.34 (0.26-0.46) < .001 
    ATG regimen vs alemtuzumab regimen 2.01 (1.49-2.72) < .001 
Non-relapse mortality§   
    ATG regimen vs T cell–replete regimen 1.34 (1.07-1.67) .01 
    Alemtuzumab regimen vs T cell–replete regimen 1.04 (0.72-1.49) .85 
    ATG regimen vs alemtuzumab regimen 1.29 (0.89-1.86) .18 
Relapse‖   
    ATG regimen vs T cell–replete regimen 1.53 (1.29-1.81) < .001 
    Alemtuzumab regimen vs T cell–replete regimen 1.54 (1.24-1.93) < .001 
    ATG regimen vs alemtuzumab regimen 0.99 (0.78-1.26) .940 
Treatment failure (inverse of disease-free survival)   
    ATG regimen vs T cell–replete regimen 1.46 (1.29-1.66) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.40 (1.17-1.68) .0003 
    ATG regimen vs alemtuzumab regimen 1.04 (0.86-1.27) .67 
Overall mortality#   
    ATG regimen vs T cell–replete regimen 1.25 (1.09-1.44) .002 
    Alemtuzumab regimen vs T cell–replete regimen 1.09 (0.87-1.36) .46 
    ATG regimen vs alemtuzumab regimen 1.15 (0.92-1.44) .22 
OutcomeHR (95% CI)P
Univariate analysis   
Grade 2-4 acute GVHD   
    ATG regimen vs T cell–replete regimen 0.98 (0.83-1.16) .82 
    Alemtuzumab regimen vs T cell–replete regimen 0.43 (0.31-0.59) < .0001 
    ATG regimen vs alemtuzumab regimen 2.29 (1.66-3.16) < .0001 
Grade 3-4 acute GVHD   
    ATG regimen vs T cell–replete regimen 0.94 (0.75-1.72) .58 
    Alemtuzumab regimen vs T cell–replete regimen 0.50 (0.33-0.75) .0008 
    ATG regimen vs alemtuzumab regimen 1.89 (1.24-2.89) .003 
Chronic GVHD   
    ATG regimen vs T cell–replete regimen 0.72 (0.62-0.85) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 0.39 (0.29-0.52) < .0001 
    ATG regimen vs alemtuzumab regimen 1.87 (1.38-2.52) < .0001 
Non-relapse mortality   
    ATG regimen vs T cell–replete regimen 1.38 (1.12-1.71) .003 
    Alemtuzumab regimen vs T cell–replete regimen 1.09 (0.79-1.51) .60 
    ATG regimen vs alemtuzumab regimen 1.27 (0.91-1.78) .17 
Relapse   
    ATG regimen vs T cell–replete regimen 1.56 (1.33-1.83) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.60 (1.29-1.99) < .0001 
    ATG regimen vs alemtuzumab regimen 0.97 (0.78-1.21) .80 
Treatment failure (inverse of disease-free survival)   
    ATG regimen vs T cell–replete regimen 1.49 (1.31-1.70) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.41 (1.18-1.70) .0002 
    ATG regimen vs alemtuzumab regimen 1.06 (0.88-1.27) .55 
Overall mortality   
    ATG regimen vs T cell–replete regimen 1.34 (1.17-1.54) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.10 (0.90-1.35) .35 
    ATG regimen vs alemtuzumab regimen 1.22 (0.99-1.50) .07 
Multivariate analysis   
Grade 2-4 acute GVHD*   
    ATG regimen vs T cell–replete regimen 0.88 (0.74-1.04) .12 
    Alemtuzumab regimen vs T cell–replete regimen 0.33 (0.24-0.46) < .001 
    ATG regimen vs alemtuzumab regimen 2.66 (1.91-3.70) < .001 
Grade 3-4 acute GVHD†   
    ATG regimen vs T cell–replete regimen 0.86 (0.69-1.08) .19 
    Alemtuzumab regimen vs T cell–replete regimen 0.42 (0.27-0.64) < .001 
    ATG regimen vs alemtuzumab regimen 2.08 (1.34-3.21) < .001 
Chronic GVHD‡   
    ATG regimen vs T cell–replete regimen 0.69 (0.59-0.81) < .001 
    Alemtuzumab regimen vs T cell–replete regimen 0.34 (0.26-0.46) < .001 
    ATG regimen vs alemtuzumab regimen 2.01 (1.49-2.72) < .001 
Non-relapse mortality§   
    ATG regimen vs T cell–replete regimen 1.34 (1.07-1.67) .01 
    Alemtuzumab regimen vs T cell–replete regimen 1.04 (0.72-1.49) .85 
    ATG regimen vs alemtuzumab regimen 1.29 (0.89-1.86) .18 
Relapse‖   
    ATG regimen vs T cell–replete regimen 1.53 (1.29-1.81) < .001 
    Alemtuzumab regimen vs T cell–replete regimen 1.54 (1.24-1.93) < .001 
    ATG regimen vs alemtuzumab regimen 0.99 (0.78-1.26) .940 
Treatment failure (inverse of disease-free survival)   
    ATG regimen vs T cell–replete regimen 1.46 (1.29-1.66) < .0001 
    Alemtuzumab regimen vs T cell–replete regimen 1.40 (1.17-1.68) .0003 
    ATG regimen vs alemtuzumab regimen 1.04 (0.86-1.27) .67 
Overall mortality#   
    ATG regimen vs T cell–replete regimen 1.25 (1.09-1.44) .002 
    Alemtuzumab regimen vs T cell–replete regimen 1.09 (0.87-1.36) .46 
    ATG regimen vs alemtuzumab regimen 1.15 (0.92-1.44) .22 
*

Model adjusted for GVHD prophylaxis, donor source, and year of transplantation.

†

Model adjusted for GVHD prophylaxis, donor source, and year of transplantation.

‡

Model adjusted for donor source and year of transplantation.

§

Model adjusted for age, performance score, conditioning regimen, GVHD, prophylaxis, and donor source.

‖

Model adjusted for performance score, disease, disease status, and conditioning regimen.

Model adjusted for age, performance score, disease, and disease status.

#

Model adjusted for age, performance score, disease, disease status, GVHD prophylaxis, and donor source.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal